The CNS market at a global scale has been one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms remain favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs.
The CNS disorders market may be segmented into numerous subcategories, including Alzheimer's disease (AD), epilepsy, insomnia, major depressive disorder (MDD), Parkinson's disease (PD), migraine, schizophrenia, attention-deficit hyperactivity disorder (ADHD), bipolar disorder among others. Antipsychotics were the largest CNS drug class. Patent expirations of key brands Seroquel and Zyprexa and many other drugs through 2012-2017 is emerging as one of the major challenges to segmental growth through 2017. The CNS sector has struggled recently, as product classes that have dominated treatment areas have come under increasing pricing pressure from generics or have been plagued with safety concerns.
The report begins with an introduction to CNS disorders. We analyze the basic CNS disorders such as ADHD, Alzheimer's disease, epilepsy, insomnia, major depressive disorder (MDD), migraine, Parkinson's disease, and Schizophrenia.
Moving to the next section, we analyze the global CNS market through a market overview and an analysis of the market by CNS drug classes. We also analyze the industry through an industry segmentation and an analysis of the leading industry products. We look at the sales figures of the leading products in the industry.
- Eli Lilly
- Johnson & Johnson
Key Topics Covered:
A. Executive Summary
B. Introduction to CNS Disorders
C. Global CNS Market
D. Factors Impacting the Market
E. Performance of Various Drug Classes
F. Upcoming/Recently Developed CNS Drugs
G. Global CNS Drugs Market Forecast
H. Competition in the Industry
I. Leading Industry Contributors
J. Glossary of Terms
K. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/research/ght2dx/global_cns_market?w=4